Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $724.8 million.

  • Syndax Pharmaceuticals' Liabilities and Shareholders Equity rose 29.59% to $551.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 22.09%. This contributed to the annual value of $724.8 million for FY2024, which is 18.26% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Liabilities and Shareholders Equity of $724.8 million as of FY2024, which was up 18.26% from $612.9 million recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Liabilities and Shareholders Equity peaked at $724.8 million during FY2024, and registered a low of $300.6 million during FY2020.
  • In the last 3 years, Syndax Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $612.9 million in 2023 and averaged $611.6 million.
  • Data for Syndax Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 373.22% (in 2020) over the last 5 years.
  • Over the past 5 years, Syndax Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $300.6 million in 2020, then spiked by 49.58% to $449.7 million in 2021, then grew by 10.58% to $497.2 million in 2022, then increased by 23.26% to $612.9 million in 2023, then climbed by 18.26% to $724.8 million in 2024.